4/17
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
4/15
04:05 pm
svra
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Medium
Report
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
4/14
08:05 am
svra
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
Low
Report
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
4/7
08:05 am
svra
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Low
Report
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
3/30
08:25 am
svra
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]
Medium
Report
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]
3/30
08:05 am
svra
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Low
Report
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
3/16
02:11 pm
svra
Savara (SVRA) was given a new $10.00 price target by William Blair.
Low
Report
Savara (SVRA) was given a new $10.00 price target by William Blair.
3/16
01:05 pm
svra
Savara (SVRA) had its "buy" rating reaffirmed by HC Wainwright.
Low
Report
Savara (SVRA) had its "buy" rating reaffirmed by HC Wainwright.
3/15
11:05 am
svra
VR Adviser Adds Over 1 Million Savara Shares [Yahoo! Finance]
Low
Report
VR Adviser Adds Over 1 Million Savara Shares [Yahoo! Finance]
3/13
08:34 am
svra
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/13
08:05 am
svra
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Low
Report
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
3/6
04:34 pm
svra
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]
Medium
Report
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]
3/6
04:05 pm
svra
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Medium
Report
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
3/6
05:40 am
svra
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed [Yahoo! Finance]
Medium
Report
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed [Yahoo! Finance]
3/4
04:05 pm
svra
Savara Announces Participation in 2026 Citizens Life Sciences Conference
Low
Report
Savara Announces Participation in 2026 Citizens Life Sciences Conference
3/1
07:53 pm
svra
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears [Yahoo! Finance]
Low
Report
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears [Yahoo! Finance]
2/20
04:15 pm
svra
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Medium
Report
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
2/13
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
2/4
04:05 pm
svra
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Medium
Report
Savara Announces Participation in Upcoming Investor Healthcare Conferences
1/27
08:05 am
svra
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
Low
Report
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
1/24
11:38 am
svra
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
1/16
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant